Italian Trade Agency at Arab Health supports 160 companies

By HEOR Staff Writer

February 1, 2023

Italian Trade Agency at Arab Health

Introduction:

The Italian Trade Agency (ITA) is a government entity promoting Italian products and services. It has thrown its weight behind 160 Italian companies participating in Arab Health 2023.

Arab Health 2023: A Global Healthcare Stage

Arab Health, an annual event that congregates healthcare professionals and companies globally. It is a platform to exhibit the latest products, services, and technological advancements in the healthcare industry. This year’s event, held in Dubai from 30th January to 2nd February, presents a spectrum of healthcare offerings, including innovations like artificial intelligence.

Italian Trade Agency at Arab Health

Located across four different halls, the Italian Pavilion provides a snapshot of Italy’s manufacturing capabilities in the healthcare sector. The pharmaceutical sector, boasting 285 companies employing 67,000 people, stands out for having the most innovative companies. The Italian pharmaceutical industry demonstrates particular prowess in biotech drugs and vaccines. Therefore, establishing Italy as a global hub for research and development (R&D) and production.

Italy’s Vision for the UAE and Sustainability Goals

Lorenzo Fanara, Italy’s Ambassador to the United Arab Emirates (UAE), and Amedeo Scarpa, Italian Trade Commissioner to the UAE, expressed Italy’s vision to strengthen business ties with the UAE, foster long-term investments, and develop industrial partnerships. Under the banner ‘Sustainability is Sustainab-ITALY’, Arab Health 2023 will focus on circular economy and sustainability, reflecting Italy’s pharmaceutical industry’s achievement in reducing energy consumption by 44% over a decade.

Conclusion:

Italian Trade Agency at Arab Health’s support for Italian healthcare companies reflects its commitment to promoting Italy’s robust healthcare sector and its vision for sustainable growth.

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
EU Joint Clinical Assessment
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices

By João L. Carapinha

June 19, 2026

EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the
LesionAttn Skin Cancer AI
LesionAttn Skin Cancer AI Enhances Fairness in Dermatological Diagnostics

By João L. Carapinha

June 19, 2026

LesionAttn Skin Cancer AI tackles a critical flaw in current skin cancer detection tools: models that unconsciously rely on background skin features differing between men and women, producing unequal accuracy across genders. By steering neural networks to focus on the actual lesion instead of the...